From its inception through to March 2005, Ibis has earned $38.5 million in revenue from government partners. An additional $13.6 million is committed under existing contracts and grants, with the potential for added funding.
“This new contract and the support we are receiving from our government partners attest to the core expertise and advanced capabilities of the Ibis division,” said Michael Treble, Isis’ vice president, and president of Ibis. “We plan to continue fostering relationships with our government partners.”
The Ibis division has developed the Triangulation Identification for Genetic Evaluation of Risks (TIGER) biosensor system, a revolutionary technology designed to identify infectious organisms.
Ibis plans to commercialize the TIGER biosensor system to government customers for use in biowarfare defense, epidemiological surveillance and forensics; and to non-government customers for use in pharmaceutical process control, hospital-associated infection control, and infectious disease diagnostics.